Mizuho downgrades Chemours stock rating on refrigerants delay
Mizuho downgraded Chemours (NYSE:CC) to Neutral from Outperform, lowering its price target to $15 from $18. The downgrade reflects slower-than-expected earnings growth from new refrigerants and concerns about titanium dioxide pigment market stability. Chemours' stock is down over 41% in the past six months, trading at $13.20. The company reported mixed Q2 2026 results, missing earnings and revenue estimates, and settled PFAS-related claims with North Carolina.
How this was made
The 30-second read
Why it matters
Analyst downgrades across the sector reinforce a bearish short-term outlook for chemical stocks.
Market read
The downgrade provides a fresh catalyst for traders to consider short positions or reduced exposure to Chemours.
What to watch
Potential upside from settlement resolution and any future regulatory relief in China.
Background
Chemours reported Q2 2026 results below expectations and settled PFAS litigation, while peers also faced rating cuts.
Ticker impact
Mizuho downgraded Chemours (CC) to Neutral and cut its price target to $15, citing slower earnings growth from refrigerants.
downward pressure as investors price in reduced earnings growth and lower target
Analyst downgrade with target cut is a fresh catalyst that typically leads to short-term sell pressure.
Market effects
Chemours' downgrade may weigh on the broader chemicals and titanium dioxide sector.
U.S. chemical stocks could see modest pullback.
Limited to investors tracking chemical industry earnings.
Counterpoint
Some investors may view the lower target as an entry point if they believe the refrigerant recovery will be faster.
Key entities
- analystMizuho
Research firm issuing the downgrade.
- companyChemours Co.
Chemical manufacturer and subject of the downgrade.
